Since inhibition of DPP4 due to genetic deletion or use of DPP4 inhibitors was shown to elevate GLP-1/GIP levels in numerous studies, this effect is the main focus of developing therapeutic targets for treatment of T2DM. Here, DPP4 is linked to type 2 diabetes mellitus.